Previous 10 | Next 10 |
Neurotrope ([[NTRP]]) has dosed the first patient in Phase 2 study of Bryostatin-1 for the treatment of Alzheimer's disease ((AD)). The study will be conducted in collaboration with the National Institutes of Health ((NIH)) under $2.7M grant to Neurotrope.The 100-subject study, will eval...
Neurotrope Announces First Patient Dosed in Long-Term Clinical Trial of Bryostatin in Alzheimer's Disease - Study Being Conducted in Collaboration with NIH Under a $2.7 Million Grant - PR Newswire NEW YORK, Oct. 6, 2020 NEW YORK , Oct. 6, 2020 /PRNewswir...
Mesoblast (MESO) -37% after FDA rejects cell therapy application for treatment-resistant graft-vs-host disease.Benitec Biopharma (BNTC) -26%.Greenpro Capital (GRNQ) -18%.Tuniu (TOUR) -14%.Hall of Fame Resort & Entertainment (HOFV) -13%.Iterum Therapeutics (ITRM) -12%.Oxbridge Re...
Gainers: CTI BioPharma (CTIC) +99%, Genetron Holdings (GTH) +26%, Allena Pharmaceuticals (ALNA) +23%, Neurotrope (NTRP) +20%, Kaleido Biosciences (KLDO) +11%.Losers: Aptorum Group (APM) -41%, Adial Pharmaceuticals (ADIL) -21%, Avalon...
Neurotrope Shareholders to Own 49 Percent of Petros Under Revised Merger Agreement with Metuchen Neurotrope Shareholders, Currently Representing 34 Percent of Shares Outstanding, Sign Agreement in Support of Merger Petros to Grow Stendra® and Explore Non-Prescription / ...
NEW YORK , July 30, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) ("Neurotrope" or the "Company") today announced that its wholly-owned subsidiary, Neurotrope Bioscience, Inc. ("NBI"), has entered into a services agreement with Worldwide Clinical Trials ("WCT") to support site...
Neurotrope (NASDAQ: NTRP ) inks an agreement with BryoLogyx to supply synthetic Bryostatin-1, manufactured by Albany Molecular Research, for its clinical trials in Alzheimer's disease and other neurodegenerative disorders and commercial use, if approved. More news on: Neurotrope, Inc., H...
DPW Holdings DPW +198% on $3.2M of defense orders . More news on: Plus Therapeutics, Inc., Genius Brands International, Inc., Fang Holdings Limited, Stocks on the move, , Read more ...
NEW YORK , June 10, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) ("Neurotrope" or the "Company") today announced its entry into a strategic agreement with BryoLogyx Inc., www.BryoLogyx.com , for the supply of synthetic, GMP-certified Bryostatin-1, manufactured by Albany Mole...
NEW YORK , May 28, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) today announced the launch of a new long-term study of Bryostatin-1 for the treatment of patients with Alzheimer's disease (AD). The Phase 2 clinical study will be conducted in collaboration with the Nation...
News, Short Squeeze, Breakout and More Instantly...
SUNRISE, FL / ACCESSWIRE / April 2, 2024 / NextTrip, Inc. (NASDAQ:NTRP) ("NextTrip", "we," "our," or the "Company"), a travel technology company, has engaged international investor relations specialists MZ Group (MZ) to lead a comprehensive strategic investor relations and financial communicat...
A look at the top 10 most actives in the United States Fisker Inc. Class A (FSR) fell 48.9% to $0.1647 on volume of 56,261,089 shares SoundHound AI Inc. (SOUN) rose 5.2% to $9.1021 on volume of 55,444,995 shares Presto Automation Inc. (PRST) rose 93.4% to $0.435 on volume of 51,103,745 sh...
Synthetic Bryostatin Available to Expand Neurodegenerative Indication Trials PR Newswire NEW YORK , Feb. 4, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX) announced today that it has received its first batch of synthetic Bryostatin. The Company has an e...